4SC AG

  • WKN: A14KL7
  • ISIN: DE000A14KL72
  • Land: Deutschland

Nachricht vom 09.01.2020 | 07:30

4SC AG: 3 upcoming conferences

DGAP-News: 4SC AG / Key word(s): Conference
09.01.2020 / 07:30
The issuer is solely responsible for the content of this announcement.

4SC AG: 3 upcoming conferences

Planegg-Martinsried, Germany, 9 January 2020 - 4SC AG (4SC, FSE Prime Standard: VSC) today announced its participation in upcoming financial and scientific conferences. 4SC's management and/or scientists will be available for one-on-one meetings at these events.

38th Annual J.P. Morgan Healthcare Conference

13 - 16 January 2020
San Francisco, CA, USA

Swiss HLG Winter Conference 2020

2 - 4 February 2020
Flüeli-Ranft, Switzerland

4th World Congress of Cutaneous Lymphomas

12 - 14 February 2020
Barcelona, Spain

- Announcement ends -
 

Further information

About 4SC

4SC AG is a clinical-stage biopharmaceutical company developing small-molecule drugs that can target key indications in cancer with high unmet medical needs. 4SC's pipeline is protected by a comprehensive portfolio of patents and currently comprises two drug candidates in clinical development: resminostat and domatinostat.

4SC aims to generate future growth and enhance its enterprise value by entering into partnerships with pharmaceutical and biotech companies and/or the eventual marketing and sales of approved drugs in select territories by 4SC itself.

4SC is headquartered in Planegg-Martinsried near Munich, Germany. The Company had 47 employees as of 30 September 2019 and is listed on the Prime Standard of the Frankfurt Stock Exchange (FSE Prime Standard: VSC; ISIN: DE000A14KL72).

Forward-looking information

Information set forth in this press release contains forward-looking statements, which involve risks and uncertainties. The forward-looking statements contained herein represent the judgement of 4SC as of the date of this press release. Such forward-looking statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond 4SC's control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. 4SC expressly disclaims any obligation or undertaking to release any updates or revisions to any such statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

 

Contact

ir-pr@4sc.com
+49 89 700763-0



09.01.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC-Fokusbox

HELMA Eigenheimbau: Klarer Kauf

Die HELMA Eigenheimbau hat mit dem Zugang weiterer Ferienimmobilienprojekte das potenzielle Umsatzvolumen um 150 Mio. € gesteigert. Ohnehin verfügt die Gesellschaft über einen umfangreichen Grundstücksbestand für das Bauträgergeschäft, womit in den kommenden Geschäftsjahren Umsätze in Höhe von über 1,4 Mrd. € realisiert werden könnten. Damit dürften unsere Schätzungen, in denen wir ein nachhaltiges Überschreiten der Umsatzmarke von 300 Mio. € annehmen, gut unterfüttert sein. Bei einem Kursziel von 65,00 € ist die HELMA-Aktie ein klarer Kauf.

News im Fokus

Deutsche Post AG: Auswirkungen des Corona - Virus und der Entscheidung zu Streetscooter

28. Februar 2020, 14:22

Aktuelle Research-Studie

2G Energy AG

Original-Research: 2G Energy AG (von First Berlin Equity Research GmbH): Hinzufügen

28. Februar 2020